Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board
20 sept. 2022 03h01 HE
|
Mainz BioMed NV
Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana...
Mainz Biomed Reports First Half 2022 Financial Results
07 sept. 2022 03h01 HE
|
Mainz BioMed NV
127% year-over-year increase in ColoAlert revenueMid-year cash balance of $26 Million BERKELEY, Calif. and MAINZ, Germany, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz...
Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference
01 sept. 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board
23 août 2022 03h01 HE
|
Mainz BioMed NV
Dr. Turgeon is an esteemed Clinical Professor at University of Michigan Health and clinical translational researcher with specific research interest in colon cancer and chemopreventionMainz Biomed’s...
Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates
16 août 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' or the “Company”), a molecular genetics diagnostic company specializing...
Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development
03 août 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board
19 juil. 2022 03h01 HE
|
Mainz BioMed NV
Renowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer DiagnosticsDr. Wang is the GI (Gastrointestinal) Division Chief at Columbia University Vagelos...
Mainz Biomed Today to Provide Corporate Update for First Half of 2022
12 juil. 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, July 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Provides Corporate Update for First Half of 2022
05 juil. 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, July 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
28 juin 2022 03h01 HE
|
Mainz BioMed NV
Multi-center clinical trial impacting ColoAlert’s profile for FDA submissionOn track to report results by early 2023 BERKELEY, Calif. and MAINZ, Germany, June 28, 2022 (GLOBE NEWSWIRE) -- Mainz...